Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.47 |
| ▸ | CCNH | P51946 | 2/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 2/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134990 | 0.90 | CSNK2A1 (0.49) | CSNK2A1CDK7CCNHMNAT1IRAK4 | |
| SCHEMBL10134997 | 0.88 | CSNK2A1 (0.53) | CSNK2A1CDK7CCNHMNAT1EGLN2 | |
| SCHEMBL13688059 | 0.85 | CSNK2A1 (0.49) | CSNK2A1CDK7CCNHMNAT1NLRP3 | |
| SCHEMBL30101099 | 0.81 | NLRP3 (0.57) | NLRP3IL1B | |
| SCHEMBL10134993 | 0.81 | CSNK2A1 (0.55) | CSNK2A1CDK7CCNHMNAT1IRAK4 | |
| SCHEMBL30101119 | 0.80 | NLRP3 (0.57) | NLRP3IL1B | |
| SCHEMBL10132264 | 0.79 | CSNK2A1 (0.43) | CSNK2A1CDK7CCNHMNAT1NLRP3 | |
| SCHEMBL10136184 | 0.78 | CSNK2A1 (0.44) | CSNK2A1KAT2B | |
| SCHEMBL10134959 | 0.77 | CSNK2A1 (0.47) | CSNK2A1CDK7CCNHMNAT1NLRP3 | |
| SCHEMBL10134992 | 0.76 | NSD2 (0.57) | CSNK2A1CDK7IRAK4EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CDK7 96/4885CCNH 351/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CDK7 96/4885CCNH 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.